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Abstract
Background: The mechanisms by which viruses cause asthma exacerbations are not precisely known. Previously,
we showed that, in ovalbumin (OVA)-sensitized and -challenged mice with allergic airway inflammation, rhinovirus
(RV) infection increases type 2 cytokine production from alternatively-activated (M2) airway macrophages, enhancing
eosinophilic inflammation and airways hyperresponsiveness. In this paper, we tested the hypothesis that IL-4 signaling
determines the state of macrophage activation and pattern of RV-induced exacerbation in mice with allergic airways
disease.
Methods: Eight week-old wild type or IL-4 receptor knockout (IL-4R KO) mice were sensitized and challenged with
OVA and inoculated with RV1B or sham HeLa cell lysate.
Results: In contrast to OVA-treated wild-type mice with both neutrophilic and eosinophilic airway inflammation,
OVA-treated IL-4R KO mice showed increased neutrophilic inflammation with few eosinophils in the airways. Like
wild-type mice, IL-4R KO mice showed OVA-induced airway hyperreactivity which was further exacerbated by RV.
There was a shift in lung cytokines from a type 2-predominant response to a type 1 response, including production of
IL-12p40 and TNF-α. IL-17A was also increased. RV infection of OVA-treated IL-4R KO mice further increased neutrophilic
inflammation. Bronchoalveolar macrophages showed an M1 polarization pattern and ex vivo RV infection increased
macrophage production of TNF-α, IFN-γ and IL-12p40. Finally, lung cells from OVA-treated IL-4R KO mice showed
reduced CD206+ CD301+ M2 macrophages, decreased IL-13 and increased TNF-α and IL-17A production by F4/80+,
CD11b+macrophages.
Conclusions: OVA-treated IL-4R KO mice show neutrophilic airway inflammation constituting a model of allergic,
type 1 cytokine-driven neutrophilic asthma. In the absence of IL-4/IL-13 signaling, RV infection of OVA-treated mice
increased type 1 cytokine and IL-17A production from conventionally-activated macrophages, augmenting
neutrophilic rather than eosinophilic inflammation. In mice with allergic airways inflammation, IL-4R signaling
determines macrophage activation state and the response to subsequent RV infection.
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Background
Macrophages are innate immune cells that play a critical
role in early phases of host defense against pathogens,
coordination of the adaptive immune response, and the
regulation of inflammation and tissue repair. Through
activation signals by various ligands and environmental
cues, macrophages may change their polarization state,
leading to altered immune responses. In the presence of
type 1 cytokines such as interferon-γ and IL-12, macro-
phages are activated in a classical manner (M1-polar-
ized) and produce pro-inflammatory cytokines and toxic
mediators. In the presence of the type 2 cytokines IL-4
and IL-13, alternatively-activated (M2-polarized) macro-
phages express a distinct pattern of phagocytic receptors
[1] and produce type 2 cytokines which play a role in
anti-parasitic and allergic responses, including asthma.
IL-13-overexpressing transgenic mice infected with C.
neoformans demonstrate alternatively-activated macro-
phages expressing Arg-1, macrophage mannose receptor
(CD206) and Ym-1, as well as lung eosinophilia, goblet
cell metaplasia, elevated mucus production and airway
hyperreactivity [2]. Adoptive transfer of IL-4Rα+ alternatively-
activated macrophages enhances eosinophilic inflammation in
ovalbumin (OVA)-sensitized and -challenged mice [3]. More-
over, CD206 is increased in the asthmatic patients and corre-
lates with the severity of asthma [4].
Viral-induced exacerbations are a major cause of
morbidity in asthma. Rhinovirus (RV), a single-stranded
RNA virus belonging to Picornavirus family, is consist-
ently the most frequent pathogen identified. However,
the precise mechanisms underlying RV-induced asthma
exacerbations are not known. Compared to normal sub-
jects, asthmatic patients with RV infection show en-
hanced neutrophilic and eosinophilic inflammation in
the lower airways [5], consistent with the notion that
asthmatics have a qualitatively different immune re-
sponse to RV infection than controls. To test this in an
animal model, we exposed OVA-sensitized and -challenged
mice with allergic airways disease to RV1B, a minor group
virus which infects mouse epithelial cells [6]. We found
that RV increased airway hyperresponsiveness and eo-
sinophilic inflammation, and that RV colocalized with
eotaxin-producing, CD68+ lung macrophages in vivo.
Macrophages from OVA-treated mice showed increased
expression of arginase-1, Ym-1 and Mgl-2, indicating a
shift in macrophage activation status, and RV inoculation
of lung macrophages from OVA-treated mice induced
expression of eotaxin-1, IL-4, and IL-13 ex vivo. Depletion
of macrophages from OVA-sensitized and -challenged
mice reduced eosinophilic inflammation following RV in-
fection. Together, these results suggest that RV causes
asthma exacerbations in part by infection of alternatively-
activated macrophages. Finally, exposure of macro-
phages from naïve mice to IL-4 and IL-13 significantly
increased RV-induced eotaxin mRNA expression, con-
sistent with the notion that type 2 cytokines are
sufficient to alter the response of macrophages to RV
infection.
In the present study, we hypothesized that IL-4 signal-
ing regulates the state of macrophage activation and
the pattern of RV-induced exacerbation in mice with
allergic airways disease. We anticipated that, in the
absence of IL-4/IL-13 signaling, RV infection would
preferentially increase type 1 cytokine production from
conventionally-activated macrophages, augmenting neu-
trophilic rather than eosinophilic inflammation. To test
this, we sensitized and challenged wild-type and IL-4 re-
ceptor knockout (IL-4R KO) mice with OVA and then
infected these animals with RV. We found that OVA-
treated IL-4R KO mice showed neutrophilic airway in-
flammation which was exacerbated by RV infection.
Macrophages from OVA-treated mice showed an M1
polarization pattern and expressed type 1 cytokines and
IL-17A in response to ex vivo RV infection. OVA-treated
IL-4R KO mice showed decreased IL-13 and increased
TNF-α and IL-17A production with RV infection by F4/
80+, CD11b+macrophages, demonstrating that IL-4R
signaling determines macrophage activation state and
the response to subsequent RV infection.
Methods
Generation of HRV
HRV1B (ATCC, Manassas, VA) were grown in cultured
HeLa cells, concentrated, partially purified and titered
as described previously [7]. Similarly concentrated and
purified HeLa cell lysates were used for sham infection.
OVA sensitization and challenge
All animal experiments were approved by the University
of Michigan Institutional Animal Care and Use Commit-
tee. Female 8 wk-old BALB/c mice (Jackson Laboratories,
Bar Harbor, MA) or age-matched BALB/c-Il4ratm1Sz/J
IL-4R KO mice (Jackson Laboratories) were injected intra-
peritoneally on days 0 and 7 with 0.2 ml PBS or a solution
of alum and 100 μg endotoxin-free OVA (Sigma-Aldrich,
St. Louis, MO). Next, mice were challenged intranasally
with 50 μl of PBS or 100 μg OVA on days 12 and 13.
RV exposure
Selected mice were inoculated intranasally with 50 μl of
1 × 108 TCID50/ml RV1B, or an equal volume of sham
control on day 14, 24 hours following the last OVA
treatment. Lungs were collected 24 hr post infection for
further analysis.
Assessment of airway responsiveness
Airway cholinergic responsiveness was assessed by meas-
uring changes in total respiratory system resistance in
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response to increasing doses of nebulized methacholine,
as described previously [8]. Mice were anesthetized with
sodium pentobarbital (50 mg/kg mouse, intraperitoneal
injection) and a tracheostomy performed. Mechanical
ventilation was conducted and total respiratory system
measured using a Buxco FinePointe operating system
(Buxco, Wilmington, NC). Airway responsiveness was
assessed by measuring changes in resistance in response
to increasing doses of nebulized methacholine.
Bone marrow-derived macrophage cultures
Femurs were harvested from naïve wild-type BALB/c
and IL-4R KO mice and the bone marrow was used to
expand macrophages for in vitro analyses. Dissociated
marrow cells were plated onto 12-well culture dishes at
1 × 106 cells/ml and cultured for 6 days in RPMI supple-
mented with 30% L929-conditioned medium and 10%
heat-inactivated fetal bovine serum [9]. Cells were stimu-
lated for 1.5 h with medium or RV1B (multiplicity of
infection, 10) and RNA harvested 8 h after infection.
Mouse bronchoalveolar inflammatory cells and
macrophage culture
Bronchoalveolar lavage (BAL) was performed using 1 ml
PBS aliquots, and differential cell counts were performed
using hematoxylin and eosin. BAL fluid from PBS- and
OVA-treated mice was seeded in 24 well plates. BAL
macrophages were purified by plastic adherence, which
yielded >90% purity. Cells were stimulated for 1.5 h in
the presence or absence of HRV1B (multiplicity of infec-
tion, 10), and harvested 8 or 24 h after infection for
RNA and protein analysis.
Cytokine/chemokine expression
Lung RNA was extracted with Trizol (Sigma-Aldrich) and
analyzed for cytokine and chemokine gene expression by
quantitative real-time PCR using specific primers and
probes. Signals were normalized to GAPDH. Primer se-
quences are shown in the Table 1. BAL fluid was spun for
15 min at 1500 rpm, and the supernatants were analyzed
for cytokine protein by multiplex immune assay (Bio-Rad,
Hercules, CA) or ELISA (R&D Systems, Minneapolis, MN).
Histology, immunohistochemistry and
immunofluorescence microscopy
Lungs were fixed with 10% formaldehyde overnight and
paraffin embedded. Blocks were sectioned at 500 μm
intervals at a thickness of 5 μm and each section was
deparaffinized, hydrated and stained with hematoxylin and
eosin. Other sections were stained with rabbit anti-mouse
IL-17A (Abcam, Cambridge, MA). For immunohistochem-
istry, sections were incubated with biotinylated secondary
goat-IgG, ABC reagent (Vector Laboratories, Burlingame,
CA), diaminobenzidine (DAB, Sigma-Aldrich) and Gill’s
hematoxylin (Fisher Scientific, Kalamazoo, MI). For fluores-
cence microscopy, slides were incubated with Alexa Fluor
(AF)-555-conjugated rat anti-mouse CD68 and AF488-
conjugated rabbit anti-mouse IL-17A or AF-conjugated
isotype control IgGs. Nuclei were stained with 4′,6-diami-
dino-2-phenylindole (DAPI). Images were visualized using
a Olympus IX71inverted phase/epifluorescence microscope
and digital CCD camera.
Flow cytometric analysis
Lungs from mice were perfused with PBS containing
EDTA, minced and digested in collagenase IV. Cells
Table 1 Primer sequence for real-time quantitative PCR
Gene Forward primer (5′ to 3′) Reverse primer (5′ to 3′)
Gapdh GTC GGT GTG AAC GGA TTT G GTC GTT GAT GGC AAC AAT CTC
Ifng TGG CTG TTT CTG GCT GTT AC TCC ACA TCT ATG CCA CTT GAG TT
Il12p40 CTC CTG GTT TGC CAT CGT TT GGG AGT CCA GTC CAC CTC TA
Il13 CCT GGC TCT TGC TTG CGT GGT CTT GTG TGA TGT TGC TCA
Il4 GGT CTC AAC CCC CAG CTA GT GCC GAT GAT CTC TCT CAA GTG AT
Tnfa ATG CAC CAC CAT CAA GGA CTC AA ACC ACT CTC CCT TTG CAG AAC TC
Il1b TGG CAG CTA CCT GTG TCT TT C GGA TGG GCT CTT CTT CAA AGA TG
Cxcl1 TGC ACC CAA ACC GAA GAA GTC AT CAA GGG AGC TTC AGG GTC AAG
Cxcl2 GCG CTG TCA ATG CCT GAA G CGT CAC ACT CAA GCT CTG GAT
Il17a CCA CGT CAC CCT GGA CTC CGG CAC TGA GCT TCC CAG AT
Il6 GGA GAG GAG ACT TCA CAG AGG ATA C TCC ACG ATT TCC CAG AGA ACA
Arg1 AAG AAT GGA AGA GTC AGT GTGG GGG AGT GTT GAT GTC AGT GTG
Ym1 AGA AGG GAG TTT CAA ACC TGG T GTC TTG CTC ATG TGT GTA AGT CA
Ccl24 ACC TCC AGA ACA TGG CGG GC AGA TGC AAC ACG CGC AGG CT
Cxcl13 CTC CAG GCC ACG GTA TTC TG CCA GGG GGC GTA ACT TGA AT
Hong et al. Respiratory Research 2014, 15:63 Page 3 of 15
http://respiratory-research.com/content/15/1/63
were filtered and washed with RBC lysis buffer, and
stimulated with for 5 h with cell stimulation cocktail
(eBioscience, San Diego, CA) containing PMA, ionomy-
cin and protein export blockers. After stimulation, dead
cells were stained with Pac-Orange Live/Dead fixable
dead staining dye (Invitrogen, Carlsbad, CA). Cells were
then stained with anti-CD45-PacBlue, anti-TCRβ-FITC,
anti-F4/80-PE-Cy5, anti-CD11c-APC, anti-CD11b-APC-
Cy7, anti-CD68-PerCP-Cy5.5, anti-CD301 conjugated
with Alexa Fluor (AF)-633 and anti-CD206 conjugated
with AF488 (all antibodies from Biolegend, San Diego,
CA). Cells were fixed, permeabilized and incubated
with anti-IL-13-PE (eBioscience), anti-IL-17A-PE-Cy7
antibody (Biolegend) or anti-TNF-α-PE-Cy7 antibody
(Biolegend). Stained cells were subjected to flow cytome-
try and analyzed on a BD Biosciences FACSAria II
(BD Biosciences, San Jose, CA). Data were collected using
FACSDiva software and analyzed using FlowJo software
(Tree Star, Ashland, OR). For controls, we substituted IgG
for all antibodies or used an FMO (fluorescence minus
one) control in which all antibodies were included except
that against the intracellular antigen.
Data analysis
Data are represented as mean ± SEM. Statistical signifi-
cance was assessed by student’s t test, unpaired t test, one-
way analysis of variance (ANOVA), two-way ANOVA,
ANOVA based on ranks, as appropriate. Differences were
pinpointed by the Bonferroni or Newman-Keuls multiple
comparisons test.
Results
We previously found that, in OVA-sensitized and -challenged
mice with allergic airway inflammation, RV infection
increases eotaxin-1, IL-4 and IL-13 production from
alternatively-activated (M2 polarized) airway macro-
phages, further enhancing eosinophilic inflammation and
airways hyperresponsiveness [6]. We also found that
in vitro exposure of macrophages from naïve mice to IL-4
and IL-13 significantly increased RV-induced eotaxin
mRNA expression, consistent with the notion that type
2 cytokines are sufficient to alter the response of
macrophages to RV infection. In the present study, we
hypothesized that IL-4 signaling determines the state of
macrophage activation and pattern of RV-induced exacer-
bation in mice with allergic airways disease. First, we
tested the responses of bone marrow-derived macro-
phages from naïve wild-type and IL-4R KO mice. We an-
ticipated that the loss of IL-4R signaling would increase
type 1 (IL-1β, TNF-α) and IL-17A-dependent (IL-17A,
CXCL1, CXCL2, IL-6) responses [10-16] to RV. Dissoci-
ated marrow cells were differentiated to macrophages
in L929-conditioned medium [9]. Macrophages from
naïve wild-type mice showed significant increases in
IL-1β, TNF-α, CXCL1 and CXCL2 mRNA expression in
response to RV infection ex vivo (Figure 1). Bone marrow-
derived macrophages from naïve IL-4R KO cells also
showed increases in IL-1β, TNF-α, CXCL1 and CXCL2
mRNA expression. However, compared to control cells,
IL-4R KO cells demonstrated significantly increased IL-1β
and CXCL2 in response to RV infection. Further, in con-
trast to cells from wild-type mice, RV infection of macro-
phages from naïve IL-4R KO mice significantly increased
mRNA expression of IL-17A and IL-6. These results sug-
gest that, in the absence of IL-4R signaling, macrophages
show an exaggerated type 1 phenotype and increased
IL-17A mRNA expression in response to RV infection.
Next, we examined the effect of IL-4R KO in mice
sensitized and challenged with OVA and infected with
RV. As previously [17], RV alone had modest effects on
airway neutrophilic inflammation and responsiveness
(not shown). As expected, OVA treatment of wild-type
mice significantly increased the total number of BAL
cells (Figure 2A), augmenting the number of neutrophils
and eosinophils (Figure 2B and C). RV infection of wild-
type mice further increased lung inflammation, resulting
in an additional 2-fold increase in BAL cells. Both
neutrophils and eosinophils were increased in the
BAL following RV infection. In IL-4R KO mice, OVA
sensitization and challenge was also accompanied
by a significant increase in BAL inflammatory cells
(Figure 2A). The inflammatory cells consisted nearly ex-
clusively of neutrophils, and the number of eosinophils
in the airways was significantly reduced compared to
wild-type mice (Figure 2B and C). When OVA-treated
IL-4R KO mice were infected with RV, neutrophil infil-
tration further increased (Figure 2B). In contrast to wild-
type mice, RV did not induce eosinophilic inflammation.
Finally, we found that, similar to wild type mice, IL-4R
KO mice showed OVA-induced airway hyperreactivity
which was further exacerbated by RV (Figure 2D and E).
(There was no difference in airway reactivity between
the wild-type and IL-4R KO OVA/RV groups.) Together,
these results show that IL-4 receptor signaling is not re-
quired for allergen-induced airway inflammation or
hyperresponsiveness. Instead, the immune responses to
OVA challenge and RV infection were differentially reg-
ulated in the absence of IL-4R signaling, accentuating
neutrophilic rather than eosinophilic inflammation.
To determine the factors driving neutrophilic inflam-
mation in IL-4R KO mice, we analyzed lung mRNA ex-
pression by qPCR (Figure 3A). In OVA-treated wild-type
mice, RV treatment increased TNF-α and IFN-γ mRNA
expression. RV infection of OVA-treated IL-4R KO mice
significantly increased TNF-α, IFN-γ, CXCL1, IL-12p40
and IL-17A mRNA levels compared to OVA alone.
Finally, compared to OVA-treated, RV-infected wild-
type mice, OVA-treated, RV-infected IL-4R KO mice
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showed increased IL-12p40 and IL-17A mRNA expres-
sion. Considering the neutrophil-recruiting ability of
TNF-α and CXCL1 [18,19], and the capacity of IL-17A
to indirectly stimulate recruitment of neutrophils into
the airways via the induction of C-X-C chemokines
[10-12,14-16], these results suggest that neutrophilic in-
flammation in the airways of OVA-treated IL-4R KO
mice was mediated, at least in part, by the induction of
TNF-α, CXCL1 and IL-17A. We also examined BAL fluid
protein levels (Figure 3B). We found that, compared to
similarly-treated wild type mice, TNF-α and IL-12p40
levels were significantly higher in the lungs of OVA-
treated, RV-infected IL-4R KO mice than wild type mice,
consistent with an enhanced type I immune response.
To examine the specific role of the macrophage in airway
neutrophilic responses, we isolated adherent BAL cells
(>90% macrophages) from OVA-sensitized and -challenged
wild-type and IL-4R KO mice and infected them with RV
ex vivo. As shown previously [6], macrophages from wild-
type mice treated with OVA expressed high levels of the
M2 marker Arg 1 and Ym-1, and expressed the type 2
cytokines IL-4 and IL-13 upon RV infection, typical of
alternative activation (Figure 4A). In contrast, macro-
phages from OVA-treated IL-4R KO mice failed to ex-
press significant levels of Arg-1 or Ym-1, and did not
express IL-4 or IL-13 mRNA with RV infection. IL-4R
KO mice also showed reduced expression of the M2a
markers CCL17 and CCL24 (Figure 4B). There was no
change in the response of IL-10 and CD86, M2b
markers (Figure 4C), or CXCL13, an M2c marker
(Figure 4D). On the other hand, IL-4R KO macrophages
showed more potent “classical” M1 cytokine responses
to RV infection, including TNF-α, IFN-γ and IL-12p40
(Figure 4E). Moreover, the basal level of IL-17A gene
expression was increased in macrophages from OVA-
treated IL-4R KO mice (Figure 4F). Finally, analysis of
macrophage supernatants confirmed increased produc-
tion of TNF-α and IL-17A protein in cells from IL-4R KO
Figure 1 Responses of bone marrow-derived macrophages to RV infection. Dissociated marrow cells from wild-type and IL-4R KO mice
were differentiated to macrophages in L929-conditioned medium. Compared to control cells, IL-4R KO cells demonstrated increased RV-induced
cytokine responses. (Mean ± SEM, n = 3, *different from medium, P < 0.05, one-way ANOVA; †different from wild-type, P < 0.05, one-way ANOVA).
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mice (Figure 4G). These results suggest that, upon OVA
treatment, IL-4R KO macrophages are polarized towards
an M1 phenotype, leading to a differential response to
RV infection compared to wild-type mice.
Next, we examined the effect of IL-4R KO on macro-
phage activation in vivo. We reasoned that, in the absence
of IL-4R signaling, RV infection of OVA-sensitized and
-challenged mice would fail to induce type 2 cytokine
production and, instead, increase type 1 and IL-17A cyto-
kine production from conventionally-activated macro-
phages, augmenting neutrophilic rather than eosinophilic
inflammation. Lungs of wild type and IL-4R KO mice
were examined by flow cytometric analysis. Lung cell sus-
pensions were stained with antibodies against macrophage
surface markers. As we found previously [6], in wild-type
mice, there was expansion of a subpopulation of cells
Figure 2 Airway inflammation and airway hyperresponsiveness in OVA-treated wild-type and IL-4R KO mice. Eight-week old wild-type or
IL-4R KO mice were treated with PBS or OVA and inoculated with sham or RV. Bronchoalveolar lavage was performed 24 hour post-inoculation.
After counting the total number of cells, cytospins were performed and stained with hematoxylin and eosin, and differential counts determined
from 200 cells. The identity of neutrophils and eosinophils was confirmed by immunofluorescence staining for neutrophil elastase and major basic
protein (not shown). (A) RV infection increases the total number of BAL cells per lung in OVA-sensitized and -challenged wild-type and IL-4R KO
mice. (B) RV infection increases the number of airway neutrophils per lung in OVA-treated wild-type and IL-4R KO mice. The neutrophil response
was significantly higher in IL-4R KO mice. (C) RV infection increases the number of airway eosinophils per lung in OVA-treated wild-type mice.
The eosinophil response was significantly attenuated in IL-4R KO mice. (Mean ± SEM, n = 3, *different from medium, p < 0.05, one-way ANOVA;
†different from wild-type, p < 0.05, one-way ANOVA.) (D & E) Airway cholinergic responsiveness was assessed by measuring changes in total
respiratory system resistance in response to increasing doses of nebulized methacholine. Data from wild type (D) and IL-4R KO mice (E) are
shown. (Mean ± SEM, n = 4-6 in each group, *different from sham, P < 0.05, two-way ANOVA; †different from PBS, P < 0.05, two-way ANOVA).
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expressing the macrophage alternative activation markers
CD206 and CD301 after OVA challenge (Figure 5A). Fur-
ther, IL-13 production by CD11b+macrophages was in-
creased with OVA treatment and further increased with RV
infection (Figure 5B and C). In contrast, in IL-4R KO mice,
there was no appearance of a new population of CD206-
and CD301-expressing cells (Figure 5A) nor was IL-13 in-
creased after OVA treatment or RV infection (Figure 5B
and C). These data suggest that IL-4 signaling is required
for alternative activation of lung macrophages and produc-
tion of effector cytokine IL-13 in this experimental system.
We asked whether type 1 cytokine production is in-
creased in macrophages from OVA-treated IL-4R KO
mice in vivo. We collected the lungs of wild type and IL-
4R KO mice, stained for TNF-α and analyzed with flow
cytometry. We sorted for CD11c- CD11b+ non-resident,
exudative macrophages [20,21]. We found that, com-
pared to wild-type mice, TNF-α producing CD45+, F4/
80+, CD11c-, CD11b+macrophages were increased in
OVA-treated IL-4R KO mice, and these cells were fur-
ther increased with RV infection (Figure 6A and B).
To test whether macrophages secrete IL-17A in vivo,
we examined the lungs of wild type and IL-4R KO mice
by flow cytometric analysis. We found that CD45+,
TCRβ-, CD68+, F4/80+, CD11c-, CD11b+, IL-17A+
macrophages were increased in naïve IL-4R KO mice
compared to wild-type mice, and further enhanced with
RV infection (Figure 6C and D). We also employed
immunohistochemistry and immunofluorescence micros-
copy to confirm IL-17A localization in lungs from OVA-
treated IL-4R KO mice. IL-17A+ monocytic cells were
evident in the subepithelium (Figure 6E). IL-17A co-
localized with CD68, a macrophage marker (Figure 6F).
Discussion
Viral-induced exacerbations are a major cause of mor-
bidity in asthma. RVs comprise approximately 50% of
the viruses isolated. However, the precise mechanisms
underlying RV-induced asthma exacerbations are not
known. RV, unlike influenza and other viruses, causes
minimal if any cytotoxicity [22,23]. The current expla-
nation is that RV infection induces the release of chemo-
kines from airway epithelial cells, thereby attracting
inflammatory cells to the airways. However, it is also
conceivable that RV directly infects airway inflammatory
cells. Several studies have examined the interaction of
Figure 3 Cytokine expression in lungs of OVA-treated wild-type and IL-4R KO mice. Wild-type or IL-4R KO mice were sensitized and
challenged with OVA and inoculated with sham or RV. (A) After 24 h, lungs were collected and gene expression measured by qPCR. (B) TNF-α,
IL-12p40 and IL-17A protein in the BAL fluid was assessed with multiplex immune assay. (Mean ± SEM, n = 3-6 each group, *different from sham,
P < 0.05, one-way ANOVA; †different from wild-type, P < 0.05, one-way ANOVA).
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monocytic cells and RV in vitro [24-32]. Recently, we
found that, in both mice and humans, RV colocalizes
with monocytes in vivo [6,33]. Following infection of
OVA-sensitized and -challenged mice, we found that
RV colocalized with eotaxin-producing, CD68+ lung
macrophages. Compared to cells from untreated mice,
BAL macrophages from allergen-treated mice showed
increased expression of type 2 and decreased expression
of type I cytokines in response to ex vivo RV infection,
indicating a shift from M1 to M2 activation status.
Finally, depletion of macrophages using clodronate lipo-
somes reduced RV-induced eosinophilic inflammation
Figure 4 Differential cytokine expression in RV-stimulated macrophages from OVA-treated wild-type and IL-4R KO mice. Macrophages
were collected from the BAL of OVA-treated wild-type or IL-4RKO mice. Macrophages were selected by allowing adherence to plastic for 2 h.
Macrophages were treated with medium or RV (multiplicity of infection, 5) for 1.5 hours. Cells were collected 8 h or 24 h after infection for RNA
and protein analysis. Gene expression in macrophage was measured by qPCR. Shown are M2 surface markers and the type 2 cytokines IL-4 and
IL-13 (A), the M2a markers CCL17 and CCL24 (B), the M2b markers IL-10 and CD68 (C), the M2c marker CXCL13 (D), the classical M1 markers
TNF-α, IFN-γ, IL-12p40 and CXCL10, IFN-α (E) and IL-17A (F). (G) TNF-α and IL-17A protein levels were assessed with ELISA. (Data represent three
independent experiments, mean ± SEM, n = 3-8 each group, *different from sham, P < 0.05, one-way ANOVA; †different from wild type, P < 0.05,
one-way ANOVA).
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and airway hyperreactivity, suggesting that RV causes
asthma exacerbations in part by infection of alternatively-
activated macrophages.
We hypothesized that IL-4 signaling drives the state of
macrophage activation and determines the pattern of
RV-induced exacerbation in mice with allergic airways
disease. To test this in an animal model, we examined
the effect of RV infection on OVA-sensitized and
-challenged wild-type and IL-4R KO mice. We antici-
pated that, in the absence of IL-4/IL-13 signaling, RV
infection would increase type 1 cytokine production
from conventionally-activated macrophages, augmenting
neutrophilic rather than eosinophilic inflammation. We
found that OVA increased the number of CD206+,
CD301+ M2-polarized lung macrophages and IL-13+
CD11b+ cells in wild type but not IL-4R KO mice. These
cells produced In addition, unlike OVA-exposed wild-
type mice with mixed neutrophilic and eosinophilic in-
flammation, OVA treatment of IL-4R KO mice induced
airway inflammation which was almost exclusively neu-
trophilic in character. When OVA-treated IL-4R KO
mice were infected with RV, neutrophil infiltration fur-
ther increased. Neutrophilic inflammation was associ-
ated with increased lung type 1 cytokine expression, and
BAL macrophages expressed type 1 cytokines in re-
sponse to RV infection ex vivo. Together, these results
show that IL-4 signaling is required for lung macrophage
M2 polarization, and that macrophage polarization state
determines the response to RV infection (Figure 7).
Many studies have demonstrated the importance of
IL-4R signaling in the regulation of the immune re-
sponse, including the response of lung macrophages
[34-36]. However, fewer studies have examined the role
of M2-polarized alternatively-activated macrophages in
the response to pulmonary infection. The loss of IL-4R-,
STAT1-dependent alternative activation has been shown
to confer resistance to RSV-induced lung injury [37],
pulmonary cryptococcosis [38-40], Mycobacterium tu-
berculosis [41] and severe acute respiratory syndrome
coronavirus (SARS-CoV) [42]. Resistance has been
attributed to the higher potential of classically activated
macrophages to produce nitric oxide [40]. In contrast, we
showed that, in allergen-sensitized and -challenged mice,
either classically- and alternatively-active macrophages
may contribute to RV-induced airway inflammation and
hyperresponsiveness. We speculate that M1 macrophages
are not protective against RV because the inflammatory
response does not depend on viral load [43].
In this study, we found that IL-17A was increased in
the lungs of OVA-treated IL-4R KO mice and expressed
by BAL and lung macrophages infected with RV. IL-17A
plays an important role in the recruitment and activation
of neutrophils following bacterial infection [11]. IL-17A
indirectly stimulates recruitment of neutrophils into
the airways via the induction of C-X-C chemokines
[10-12,14-16]. Production of IL-17A was first reported
in CD4+ cells [44]. IL-17A-producing Th17 cells are
regarded as a distinct subset of T cells, divergent from
Th1 and Th2 cells. It is now established that neutrophils,
eosinophils and macrophages also produce IL-17A
[14,45,46]. It was recently shown that IL-13 signaling in-
hibits IL-17A production from CD4+ Th17 cells [47].
Thus, it is likely that, in our study, IL-17A production
was derepressed in IL-4R KO mice deficient in IL-13 sig-
naling. Further, we found that, in the absence of IL-4R
signaling, BAL macrophages from OVA-treated mice
were polarized to produce IL-17A as well as type 1 cyto-
kines. Macrophage IL-17A production likely contributed
to the observed neutrophilic inflammation.
We found that OVA-treated IL-4R KO mice showed
neutrophilic airway inflammation, essentially constitut-
ing a model of allergic, type 1 cytokine-driven neutro-
philic asthma. IL-4 KO mice have previously shown
increased neutrophils upon ovalbumin exposure [35].
Although the allergic type 2 immune response has been
considered as a hallmark of asthma, only 50% of asthma
cases are due to eosinophilic inflammation, the rest
showing airway neutrophils [48]. This type of asthma
has been associated with specific asthma phenotypes in-
cluding severe asthma, corticosteroid-resistant asthma,
nocturnal asthma and occupational asthma [49-57]. Al-
though non-allergic stimuli, for example, lipopolysac-
charide and ozone [58-60], have been associated with
neutrophilic airway inflammation, our data are consist-
ent with the notion that a subset of allergic patients may
experience neutrophilic rather than eosinophilic airway
inflammation due to the influence of type 1 cytokines
and IL-17A. While we did not determine the precise
(See figure on previous page.)
Figure 5 Differential expansion of CD206+ CD301+ M2-polarized macrophages and IL-13 production in wild-type and IL-4R KO mice.
Eight-week old wild-type or IL-4R KO mice were treated with PBS or OVA by intraperitoneal injection (days 0, 7) and intranasal installation (days
12, 13). Mice were intranasally inoculated with sham or RV on day 14. Lungs were harvested and minced in collagenase IV solution. (A) Cells were
stained with antibodies against macrophage surface markers and assessed with flow cytometric analysis. CD206- and CD301-double positive cells
in the CD11b+ cell fraction are shown. (B) Cells were incubated with cell stimulation cocktail for 5 h, stained, and analyzed with flow cytometric
method. Expression of CD11b and IL-13 was analyzed among CD45+ cells. The numbers represent the percentage of cells within each quadrant.
For the control, IgG was substituted for all antibodies. (C) The percentage of CD11b + IL-13+ cells were shown among CD45+ fraction. N = 4,
*different from PBS sham group, p < 0.05, ANOVA.
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mediators driving airway hyperresponsiveness in the
absence of IL-4R signaling, we suspect that macrophage-
and neutrophil-derived TNF-α plays a role. TNF-α mRNA
and protein expression were increased in the lungs and
lung macrophage supernatants of OVA-exposed, RV-
infected IL-4R KO mice. In addition, we have shown that
TNF-α is required for RV-induced airways responsiveness
in naïve mice [61].
We would like to note some limitations of our animal
model. Species differences between human and mouse
partially restrict viral replication, thereby requiring a
higher inoculum However, we have demonstrated viral
replication and IFN responses following inoculation of
mice with human RV [17]. We have also shown that the
inflammatory response to RV infection is greater than
that to UV-irradiated virus, sham-infected HeLa cell
lysate, and filtrates from RV-infected HeLa cell lysates
[62]. Another potential concern relates to our model’s
dependence on minor group viruses. However, effects of
RV1B infection on wild-type mice are indistinguishable
from those of RV16, a major group virus, on transgenic
human ICAM-1 mice [63]. Major and minor group vi-
ruses induce nearly identical patterns of gene expression
in cultured airway epithelial cells [64]. Analysis of all RV
genomes revealed that RV1 and 16 are highly homolo-
gous and respond similarly to antiviral compounds [65],
implying that the distinction between some major and
minor group strains may not be clinically relevant.
Conclusion
We showed that, in contrast to sensitized and challenged
wild-type mice with mixed neutrophilic and eosinophilic
(See figure on previous page.)
Figure 6 TNF-α and IL-17A expression in macrophages of wild-type and IL-4R KO mice. Wild-type or IL-4R KO mice were sensitized and
challenged with OVA, and selected mice were inoculated with sham or RV. (A) Lungs were harvested and digested with collagenase IV. Cells
were stimulated with cell stimulation cocktail for 5 h and stained with antibodies against macrophage surface markers, fixed, permeabilized
and incubated with anti-TNF-α. CD11b + TNF-α + cells were analyzed in the CD45+ F4/80+ CD11c- fraction. A fluorescent minus one (FMO)
control was utilized to confirm TNF-α signals. In this control, cells were incubated with all antibodies except anti-TNF-α. (B) The percentage of
CD45+, F4/80+, CD11c-, CD11b+, TNF-α cells in the CD45+ F4/80+ CD11c- fraction (upper panel) and total CD45+ TNF-α + cells (lower panel)
were calculated. (C) IL-17A producing macrophages were assessed by flow cytometry. Lung cells were stained with anti-IL-17A. CD45+, CD68+,
F4/80+, CD11c- cells were analyzed for CD11b and IL-17A. An FMO control (all antibodies except anti-IL-17) was used to confirm IL-17 signals.
(D) The percentage of CD45+, CD68+, F4/80+, CD11c-, CD11b+, IL-17A + cells in the CD45+ CD68+ fraction (upper panel) and total CD45+ IL-17A +
cells (lower panel) were calculated. (E) Lung sections were stained with anti-IL-17A antibody. Immunohistochemistry shows DAB staining of round
cells in the airway subepithelium. (F) Lungs were stained with AF555-conjugated anti-CD68 (red) and AF488-conjugated anti-IL-17A (green). Nuclei
were stained with DAPI (blue). Immunofluorescence shows colocalization (yellow), indicating IL-17A production by CD68+ macrophages. (Mean ± SEM,
n = 3-5 each group, *different from sham, P < 0.05, one-way ANOVA; †different from wild-type, P < 0.05, one-way ANOVA).
Figure 7 Macrophage activation state determines the response to subsequent rhinovirus infection. Upon airway injury, individuals with a
type 2-predominant immune response experience eosinophilic airway inflammation which is heightened by RV infection. Alternatively, individuals with
a type 1/IL-17-predominant response (analogous to IL-4R KO mice) demonstrate neutrophilic inflammation which is exacerbated by RV infection.
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inflammation, IL-4R KO mice sensitized and challenged
with OVA have significant neutrophilic inflammation
which is further enhanced by RV infection. Macrophages
from OVA-treated IL-4R KO mice showed an M1
polarization pattern and expressed type 1 cytokines and
IL-17A in response to RV infection. We conclude that,
in allergen-sensitized mice, the macrophage activation
state determines the response to RV infection.
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